EYET Eyetech Pharmaceuticals (MM)

Eyetech to Present at the 23rd Annual JPMorgan Healthcare Conference NEW YORK, Jan. 4 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) today announced that it will present at the 23rd Annual JPMorgan Healthcare Conference in San Francisco, California on Monday, January 10, 2005, at 3:30 p.m., Pacific Time. Interested parties may access a live audio webcast of the presentation by logging on to the Investor Relations section of our corporate website at http://www.eyetech.com/ . Alternatively, the webcast may also be accessed through the Healthcare Webcast Website at http://equityconferences.jpmorgan.com/ . An archived version of the webcast will be available at both locations through January 24, 2005. About Eyetech Pharmaceuticals, Inc. Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye. Eyetech is commercializing and further developing Macugen(R) (pegaptanib sodium injection) with Pfizer Inc for the treatment of neovascular age-related macular degeneration. Macugen is also being studied for the treatment of diabetic macular edema and retinal vein occlusion. DATASOURCE: Eyetech Pharmaceuticals, Inc. CONTACT: Karin Hehenberger, M.D., Ph.D., Senior Director of Scientific and External Affairs, +1-212-824-3176, (Facsimile) +1-212-824-3240, Web site: http://www.eyetk.com/ http://www.eyetech.com/ http://equityconferences.jpmorgan.com/

Copyright